OSL · NYKD.OL
Nykode Therapeutics AS
NOK 3.06+NOK 0.04 (+1.16%)
Nykode Therapeutics AS’s quoted price sits in the lower half of its reported 52-week range, 41.25% below the high.
Loading market information…
OSL · NAVA.OL · NOK
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 09:05 AM UTC. Cached market data; not a live quote.
One-year closing-price history · NOK. Historical prices are not a forecast.
Navamedic ASA’s quoted price sits in the lower half of its reported 52-week range, 57.55% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Navamedic ASA’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Navamedic ASA, an Oslo, Norway-based pharmaceutical firm established in 2002 and formerly known as Glucomed AS until its name change in 2004, operates across Northern Europe. The company is actively involved in the entire lifecycle of pharmaceutical and related goods, from development and manufacturing to their commercialization and distribution. Its comprehensive portfolio encompasses a diverse range of products, including prescribed and over-the-counter medications, specialized medical nutrition, medical devices, dietary supplements, and cosmetic items. A significant portion of its offerings is dedicated to medical nutrition, formulated to address various metabolic disorders such as phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders. These nutritional solutions also cater to conditions like glycogen storage diseases, renal diseases, fat metabolism issues, malnutrition, and support for ketogenic diets. Furthermore, Navamedic features a consumer health division providing non-prescription drugs and wellness products for common ailments including pain relief, coughs, colds, gastrointestinal issues, and women's health, primarily distributed through pharmacies and drugstores. The company also supplies specialty pharmaceuticals targeting specific therapeutic areas such as dermatology, wound care, women's health, urology, and obesity. Completing its product line are branded generics, notably in cardiology and antibiotics. Its widespread distribution network ensures products reach hospitals, individual patients, and retail pharmacies throughout its operational regions.
Latest available per-share figures in NOK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| NOK 137.28M-2.36% vs estimate |
| Q1 2025 | Apr 30, 2025 | -NOK 0.07-114.07% vs estimate | NOK 132.02M+2.11% vs estimate |
|---|
| Q4 2024 | Feb 12, 2025 | -NOK 0.75-859.98% vs estimate | NOK 131.20M+0.04% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NOK 3.06+NOK 0.04 (+1.16%)
Nykode Therapeutics AS’s quoted price sits in the lower half of its reported 52-week range, 41.25% below the high.
NOK 38.60NOK 0.00 (0.0%)
Gentian Diagnostics AS’s quoted price sits in the lower half of its reported 52-week range, 35.67% below the high.
NOK 7.74+NOK 0.24 (+3.2%)
Lytix Biopharma AS’s quoted price sits in the lower half of its reported 52-week range, 34.96% below the high.
NOK 1.30NOK 0.00 (0.0%)
Hofseth BioCare ASA’s quoted price sits in the lower half of its reported 52-week range, 37.14% below the high.
NOK 4.37-NOK 0.13 (-2.89%)
ContextVision AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 24.39% below the high.
NOK 0.44+NOK 0.01 (+2.69%)
Lifecare AS’s quoted price sits in the lower half of its reported 52-week range, 92.81% below the high.
NOK 5.00-NOK 0.20 (-3.85%)
CodeLab Capital AS’s quoted price sits in the upper half of its reported 52-week range, 18.83% below the high.
NOK 2.28+NOK 0.08 (+3.64%)
Arctic Bioscience AS’s quoted price sits in the lower half of its reported 52-week range, 45.71% below the high.
